The initiation of patient enrolment in the STARS DAPT trial marks an important milestone for Abluminus np. While contemporary ...
SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback